Incyte's Opzelura Wins EU Approval for Atopic Dermatitis

The European Commission has approved Incyte's Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis whose disease is not adequately controlled by topical corticosteroids and topical calcineurin inhibitors, or for whom those therapies are inappropriate . The clearance makes Opzelura the first steroid-free topical JAK inhibitor approved in the EU for atopic dermatitis .

The decision follows the positive opinion issued in June 2026 by the EMA's Committee for Medicinal Products for Human Use, so the approval itself was widely expected rather than a surprise . The supporting TRuE-AD4 trial showed statistically significant improvement at week 8 versus vehicle cream, with efficacy maintained through week 24 on as-needed use . Opzelura has been approved in the United States for atopic dermatitis since 2021, so this is geographic expansion of an established asset rather than a new indication.

The commercial question is concentration. Opzelura is INCY's principal growth driver outside the Jakafi franchise, and a European launch adds a large addressable population against national reimbursement negotiations that will set realistic uptake. Commentary around the approval has focused on whether the market has already priced it in given the June CHMP signal.

What to watch: country-level reimbursement decisions in the major EU markets, first disclosed European Opzelura contribution on the next quarterly report, and whether steroid-free positioning translates into prescriber switching from established topical therapy rather than incremental use.

Related Stocks

• INCY